124 related articles for article (PubMed ID: 36194532)
1. Preclinical Model to Evaluate Outcomes of Amyloid Cross-Toxicity in the Rodent Brain.
Henríquez G; Méndez L; Castañeda E; Wagler A; Jeon S; Narayan M
ACS Chem Neurosci; 2022 Oct; 13(20):2962-2973. PubMed ID: 36194532
[TBL] [Abstract][Full Text] [Related]
2. An 11-mer Amyloid Beta Peptide Fragment Provokes Chemical Mutations and Parkinsonian Biomarker Aggregation in Dopaminergic Cells: A Novel Road Map for "Transfected" Parkinson's.
Kabiraj P; Marin JE; Varela-Ramirez A; Narayan M
ACS Chem Neurosci; 2016 Nov; 7(11):1519-1530. PubMed ID: 27635664
[TBL] [Abstract][Full Text] [Related]
3. A Hybrid Model to Study Amyloid Cross-Toxicity.
Henriquez G; Mendez L; Narayan M
ACS Chem Neurosci; 2020 Feb; 11(3):228-230. PubMed ID: 31920071
[TBL] [Abstract][Full Text] [Related]
4. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
Martinez-Valbuena I; Amat-Villegas I; Valenti-Azcarate R; Carmona-Abellan MDM; Marcilla I; Tuñon MT; Luquin MR
Acta Neuropathol; 2018 Jun; 135(6):877-886. PubMed ID: 29536165
[TBL] [Abstract][Full Text] [Related]
5. The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation.
Galzitskaya OV; Grishin SY; Glyakina AV; Dovidchenko NV; Konstantinova AV; Kravchenko SV; Surin AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835194
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson's Disease.
Werner T; Horvath I; Wittung-Stafshede P
J Parkinsons Dis; 2020; 10(3):819-830. PubMed ID: 32538869
[TBL] [Abstract][Full Text] [Related]
7. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery.
Di Scala C; Armstrong N; Chahinian H; Chabrière E; Fantini J; Yahi N
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362170
[TBL] [Abstract][Full Text] [Related]
8. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
9. Interactions of amyloidogenic proteins.
Giasson BI; Lee VM; Trojanowski JQ
Neuromolecular Med; 2003; 4(1-2):49-58. PubMed ID: 14528052
[TBL] [Abstract][Full Text] [Related]
10. Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice.
Emmer KL; Covy JP; Giasson BI
Neurosci Lett; 2012 Jan; 507(2):137-42. PubMed ID: 22188655
[TBL] [Abstract][Full Text] [Related]
11. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
[TBL] [Abstract][Full Text] [Related]
13. General Aggregation-Induced Emission Probes for Amyloid Inhibitors with Dual Inhibition Capacity against Amyloid β-Protein and α-Synuclein.
Jia L; Wang W; Yan Y; Hu R; Sang J; Zhao W; Wang Y; Wei W; Cui W; Yang G; Lu F; Zheng J; Liu F
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31182-31194. PubMed ID: 32584021
[TBL] [Abstract][Full Text] [Related]
14. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR
Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546
[TBL] [Abstract][Full Text] [Related]
15. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
16. The Amyloid Forming Peptides Islet Amyloid Polypeptide and Amyloid β Interact at the Molecular Level.
Wang Y; Westermark GT
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681811
[TBL] [Abstract][Full Text] [Related]
17. Degradation Products of Amyloid Protein: Are They The Culprits?
Zaretsky DV; Zaretskaia M
Curr Alzheimer Res; 2020; 17(10):869-880. PubMed ID: 33272185
[TBL] [Abstract][Full Text] [Related]
18. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
[TBL] [Abstract][Full Text] [Related]
19. Amyloid cross-seeding raises new dimensions to understanding of amyloidogenesis mechanism.
Chaudhuri P; Prajapati KP; Anand BG; Dubey K; Kar K
Ageing Res Rev; 2019 Dec; 56():100937. PubMed ID: 31430565
[TBL] [Abstract][Full Text] [Related]
20. Gut power: Modulation of human amyloid formation by amyloidogenic proteins in the gastrointestinal tract.
Wittung-Stafshede P
Curr Opin Struct Biol; 2022 Feb; 72():33-38. PubMed ID: 34450484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
